Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew

European Journal of Pharmacology

Volumn 563, Issue 1-3, 2007, Pages 187-196

  Darmani, Nissar A ^a   Janoyan, Jano J ^a   Crim, Jennifer ^a   Ramirez, Juan ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

8 THC; 9 THC; Cannabinoid; CB1 receptor; CB2 receptor; CP55,940; Least shrew; Radiation; SR141716A; SR144528; Vomit; WIN55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; ISOMER; MALE; NONHUMAN; PRIORITY JOURNAL; RADIATION INDUCED EMESIS; SHREW; WHOLE BODY RADIATION;

ANIMALS; ANTIEMETICS; BENZOXAZINES; CANNABINOIDS; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; GAMMA RAYS; LOCOMOTION; MORPHOLINES; NAPHTHALENES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SHREWS; TETRAHYDROCANNABINOL; VOMITING;

EID: 34247136816     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.01.093     Document Type: Article

References (45)

1. Abrahamov A., Abrahamov A., and Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 56 (1995) 2097-2102
2. Costall B., Domeney A.M., Naylor R.J., and Tattersal F.D. Emesis induced by cisplatin in the ferret as a model for the detection of antiemetic drugs. Neuropharmacology 26 (1987) 1321-1326
3. Churchfield, S., 1990. The Natural History of Shrews. Cornell Univ. Press, Comstock Publishing Associates, Ithaca, NY.
4. Daley-Yates P.T., and McBrien D.C.H. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumor activity of cisplatin. Biochem. Pharmacol. 33 (1984) 3063-3070
5. Darmani N.A. Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis. J. Neurol Trans. 105 (1998) 1143-1154
6. 1 receptors in the least shrew. Pharmacol. Biochem. Behav. 69 (2001) 239-249
7. Darmani N.A. The cannabinoid antagonist/inverse agonist SR 141716A reverses the antiemetic and motor depressant action of WIN 55, 212-2 in the least shrew. Eur. J. Pharmacol. 430 (2001) 49-58
8. 1 receptor antagonist/inverse agonist SR141716A. Neuropsychopharmacology 24 (2001) 198-203
9. 2A receptor-mediated behaviors in mice. Pharmacol. Biochem. Behav. 68 (2001) 311-317
10. 9-tetrahydrocannabinol and synthetic cannabinoids in chemotherapy-induced nausea and vomiting. In: Onaivi E.S., Sugiura T., and DiMarzo V. (Eds). Biology of Marijuana from Gene to Behavior (2002), Taylor and Francis, London 356-389
11. 9-tetrahydrocannabinol and other cannabinoids. J. Pharmacol. Exp. Ther. 300 (2002) 34-42
12. Darmani N.A. Endocannabinoids and gastrointestinal function. In: Onaivi E.S., Sugiura T., and Di Marzo R. (Eds). Endocannabinoids. The Brain and Body's Marijuana and Beyond (2006), CRC/Taylor and Francis, Boca Raton 395-419
13. Darmani N.A., and Crim J.L. Delta-9-tetrahydrocannabinol prevents emesis more potently than enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol. Biochem. Behav. 80 (2005) 35-44
14. 9-THC against 5-hydroxytryptophan-induced emesis. Eur. J. Pharmacol. 488 (2004) 201-212
15. 1 receptor characterization, distribution and G-protein activation. Eur. J. Pharmacol. 459 (2003) 83-95
16. Darmani N.A., Zhao W., and Ahmad B. The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J. Neurol. Trans. 106 (1999) 1045-1061
17. Feyer P.Ch., Maranzano E., Molassiotis A., Clark-Snow R.A., Roila F., Warr D., and Olver I. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support. Care Cancer 13 (2005) 122-128
18. Govaerts S.J., Hermans E., and Lambert D.M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur. J. Pharm. Sci. 23 (2004) 233-243
19. Griffin A.M., Butow P.N., Coates A.S., Childs A.M., Ellis P.M., Dunn S.M., and Tattersal M.H. On the receiving end. V: Patients perceptions of the side effects of cancer chemotherapy in 1993. Ann. Oncol. 7 (1996) 189-195
20. Hesketh P.J., Van Belle S., Aapro M., Tattersal F.D., Naylor R.J., Hargreaves R., Carides A.D., Evans J.K., and Horgan K.J. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Pharmacol. 39 (2003) 1074-1080
21. Jereczek-Fossa B.A., Marsiglia H.R., and Orecchia R. Radiotherapy related fatigue: how to assess and how to treat the symptom. A commentary. Tumori 87 (2001) 147-151
22. Jones W.G., Fossa S.D., Mead G.M., Roberts J.W., Sokal M., Horwich A., and Stenning S.P. Randomized trial of 30 versus 20 Gy in the adjuvent treatment of stage I testicular seminoma. A report on medical research conical trial TE18, European Organization for the research and treatment of cancer trial 30942 (ISRCTN18525328). J. Clin. Oncol. 23 (2005) 1200-1208
23. Kayl A.E., and Meyers C.A. Side effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr. Opin. Obstet. Gynecol. 18 (2006) 24-28
24. King G.L. Characterization of radiation-induced emesis in the ferret. Radiat. Res. 114 (1988) 599-612
25. King G.L. Animal models in the study of vomiting. Can. J. Physiol. Pharm. 68 (1990) 260-268
26. King G.L., and Landauer M.R. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret. J. Pharmacol. Exp. Ther. 235 (1990) 1026-1033
27. Kwiatkowska M., Parker L.A., Burton P., and Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 147 (2004) 254-259
28. London S.W., McCarthy L.E., and Borrison H.L. Suppression of cancer chemotherapy-induced vomiting in the cat by nabilone, a synthetic cannabinoid. Proc. Soc. Exp. Biol. Med. 160 (1979) 437-440
29. Lucraft H.H., and Palmer M.K. Randomized clinical trials of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin. Radiol. 33 (1982) 621-622
30. Maranzano E. Radiation-induced emesis: a problem with many open questions. Tumori 87 (2001) 213-218
31. Maranzano E., Feyer P.C., Molassiotis A., Rossi R., Clark-Snow R.A., Olver I., Warr D., Schiavone C., and Roila R. Evidence based recommendations for the use of antiemetics in radiotherapy. Radiother. Oncol. 76 (2005) 227-233
32. Onaivi E.S., Ishiguro H., Zhang P.W., Lin Z., Akinshola B.E., Leonard C.M., Chirwa S.S., Gong J., and Uh G.R. Endocannabinoid receptor genetics and marijuana use. In: Onaivi E.S., Sugiura T., and Di Marzo V. (Eds). Endocannabinoids. The Brain and Body's Marijuana and Beyond (2006), CRC/Taylor and Francis, Boca Raton 57-118
33. Osoba D., Zee B., Warr D., Kaizer L., Latreille J., and Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology 5 (1996) 92-95
34. Pertwee R.G. Cannabis and cannabinoids: pharmacology and rational clinical use. Forsch. Komplement. 3 (1999) 12-15
35. 3 receptor antagonists on cisplatin-induced emesis in the pigeon. Eur. J. Pharmacol. 221 (1992) 343-350
36. Priestman S.G., Priestman T.G., and Canny P.A. A double-blind randomized cross-over comparison of nabilone and metoclopramide in the control of radiation. Clin. Radiol. 38 (1987) 543-544
37. Razdan R. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38 (1986) 75-149
38. 3 receptor antagonists and dexamethasone to modify cisplatin-induced emesis in Suncus marinus (house musk shrew). Eur. J. Pharmacol. 472 (2003) 135-145
39. Scarantino C.W., Ornitz R.D., Hoffman L.G., and Anderson Jr. R.F. On the mechanism of radiation-induced emesis: the role of serotonin. Int. J. Radiat. Oncol. Biol. Phys. 30 (1994) 825-830
40. Ungerleider J.T., Andrysiak T., Fairbanks L., Goodnight J., Sarna G., and Jamison K. Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 50 (1982) 636-645
41. Van der Meeren A., and Lebaron-Jacobs L. Behavioral consequences of an 8 Gy total body radiation in mice: regulation by interleukin 4. Can. J. Physiol. 79 (2001) 140-143
42. 2 receptors. Science 310 (2005) 329-332
43. 1 receptors in the brainstem of the ferret. Gastroenterology 121 (2001) 767-774
44. 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am. J. Physiol.: Gasterointest. Liver Physiol. 285 (2003) G566-G576
45. Veyrat-Follet C., Farinotti R., and Palmer J.L. Physiology of chemotherapy-induced emesis and antiemetic therapy. Drugs 53 (1997) 206-234